XOMA (NASDAQ:XOMA) Stock Rating Upgraded by StockNews.com

XOMA (NASDAQ:XOMA) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.

Separately, HC Wainwright reiterated a “buy” rating and set a $104.00 price target on shares of XOMA in a report on Friday, March 28th.

XOMA Trading Down 2.4 %

Shares of XOMA stock opened at $19.70 on Friday. The company has a market cap of $235.47 million, a PE ratio of -5.66 and a beta of 1.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The stock’s 50 day simple moving average is $22.26 and its two-hundred day simple moving average is $26.25. XOMA has a 1 year low of $18.35 and a 1 year high of $35.00.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. The company had revenue of $8.70 million during the quarter, compared to the consensus estimate of $8.75 million. Research analysts predict that XOMA will post -1.41 earnings per share for the current year.

Insider Buying and Selling at XOMA

In other news, Director Joseph M. Limber purchased 17,935 shares of the company’s stock in a transaction dated Thursday, April 3rd. The shares were acquired at an average price of $25.24 per share, with a total value of $452,679.40. Following the transaction, the director now owns 16,524 shares of the company’s stock, valued at $417,065.76. This represents a -1,271.08 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CIO Bradley Sitko purchased 4,134 shares of the business’s stock in a transaction dated Friday, March 21st. The shares were purchased at an average price of $23.89 per share, for a total transaction of $98,761.26. Following the purchase, the executive now owns 10,484 shares of the company’s stock, valued at approximately $250,462.76. This trade represents a 65.10 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 29,312 shares of company stock valued at $735,061 in the last quarter. 7.20% of the stock is owned by insiders.

Hedge Funds Weigh In On XOMA

Institutional investors have recently bought and sold shares of the business. Nuveen Asset Management LLC boosted its position in XOMA by 3.8% during the 4th quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 527 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the last quarter. New York State Common Retirement Fund lifted its stake in shares of XOMA by 51.2% during the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 800 shares during the last quarter. Eversept Partners LP grew its stake in XOMA by 1.2% in the fourth quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company’s stock valued at $2,508,000 after purchasing an additional 1,128 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after purchasing an additional 1,138 shares during the last quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.